2. Anti-infection Epigenetics Cell Cycle/DNA Damage Apoptosis Autophagy PI3K/Akt/mTOR
  3. Bacterial PARP Caspase Apoptosis Autophagy Akt
  4. BV02

BV02 is a 14-3-3 inhibitor and an antibacterial agent. BV02 enhances the cleavage of PARP and caspase-3. BV02 induces Apoptosis, Autophagy, and enhances Akt activation. BV02 has anti-B. melitensis infection and epilepsy-promoting effects. BV02 can also be used in colitis research.

For research use only. We do not sell to patients.

BV02 Chemical Structure

BV02 Chemical Structure

CAS No. : 292870-53-2

Size Price Stock Quantity
Free Sample (0.1 - 0.5 mg)   Apply Now  
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Solid
5 mg In-stock
10 mg In-stock
25 mg In-stock
50 mg In-stock
100 mg In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

BV02 Related Antibodies

Top Publications Citing Use of Products

1 Publications Citing Use of MCE BV02

View All PARP Isoform Specific Products:

View All Isoforms
PARP PARP1 PARP2 PARP3 PARP4 TNKS1/PARP5A TNKS2/PARP5B PARP7 PARP10 PARP14 PARP15 PARP12 PARP16

View All Caspase Isoform Specific Products:

View All Isoforms
Caspase 1 Caspase 2 Caspase 3 Caspase 4 Caspase 5 Caspase 6 Caspase 7 Caspase 8 Caspase 9 Caspase 10 Caspase 12 Caspase Caspase 11 Caspase-13

View All Akt Isoform Specific Products:

View All Isoforms
Akt Akt1 Akt2 Akt3

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

BV02 is a 14-3-3 inhibitor and an antibacterial agent. BV02 enhances the cleavage of PARP and caspase-3. BV02 induces Apoptosis, Autophagy, and enhances Akt activation. BV02 has anti-B. melitensis infection and epilepsy-promoting effects. BV02 can also be used in colitis research.

IC50 & Target[4]

Caspase-3

 

In Vitro

BV02 (5 μM; 24 h) induces apoptotic death and recruits cells into the sub-G1 phase of the cell cycle in Bcr-Abl-expressing Ba/F3 cells, regardless of whether they express the wild-type Bcr-Abl or the T315I mutation[1].
BV02 (5-50 μM; 24 h) significantly reduces the surface expression of wild-type K2P5.1-GFP channels in HEK293T cells[2].
BV02 (5 μM; 6 h) induces autophagy in C33A cells, with increasing the LC3-II level and decreasing the SQSTM1 level[3].
BV02 (5 μM; 36 h) enhances Akt activation, as shown by increased phosphorylation of Akt at Thr308 and Ser473, and triggers apoptosis in SW480 cells[4].
BV02 (20 μM; 24 h) decreases the invasion of Brucella into macrophages[7].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

BV02 Related Antibodies

Western Blot Analysis[4]

Cell Line: SW480 cells
Concentration: 5 μM
Incubation Time: 36 h
Result: Increased the phosphorylation of Akt at Thr308 and Ser473.
Augmented the cleavage of PARP and caspase-3, indicating apoptosis.
Decreased the level of p-Hist3, a marker of cell proliferation.
In Vivo

BV02 (10 mg/kg; i.p.; once daily; 4 days during DSS-induced colitis) enhances Akt activation in the mucosa of colitic mice, increases apoptosis, and decreases cell proliferation, further shortening the colon length[4].
BV02 (10 mg/kg; i.p.; 1 day prior to receiving PTZ) weakens the anti-epileptic effects of LV-14-3-3 and LV-HAP1 in Pentylenetetrazole (PTZ)-induced epileptic rats, increasing seizure severity, shortening latency and increasing generalized tonic clonic (GTC) values per rat[5].
BV02 (3 mg/kg; i.p.; once daily; for 3 days starting 10 days post - infection) reduces the splenic load of B. melitensis in infected mice[6].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Molecular Weight

377.36

Formula

C20H15N3O5
CAS No.
Appearance

Solid

Color

White to off-white

SMILES

O=C(C1=CC2=C(C(N(C3=C(C)N(C)N(C4=CC=CC=C4)C3=O)C2=O)=O)C=C1)O
Shipping

Room temperature in continental US; may vary elsewhere.
Storage
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
Solvent & Solubility
In Vitro: 

DMSO : 12.5 mg/mL (33.13 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.6500 mL 13.2501 mL 26.5002 mL
5 mM 0.5300 mL 2.6500 mL 5.3000 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 1.25 mg/mL (3.31 mM); Clear solution

    This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 1.25 mg/mL (3.31 mM); Clear solution

    This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation

Purity: 99.75%

SDS (399 KB)

COA (252 KB) HNMR (267 KB) LCMS (97 KB)

Handling Instructions (2659 KB)
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 2.6500 mL 13.2501 mL 26.5002 mL 66.2504 mL
5 mM 0.5300 mL 2.6500 mL 5.3000 mL 13.2501 mL
10 mM 0.2650 mL 1.3250 mL 2.6500 mL 6.6250 mL
15 mM 0.1767 mL 0.8833 mL 1.7667 mL 4.4167 mL
20 mM 0.1325 mL 0.6625 mL 1.3250 mL 3.3125 mL
25 mM 0.1060 mL 0.5300 mL 1.0600 mL 2.6500 mL
30 mM 0.0883 mL 0.4417 mL 0.8833 mL 2.2083 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

BV02 Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

BV02292870-53-2BV 02BV-02BacterialPARPCaspaseApoptosisAutophagyAktpoly ADP ribose polymerase PKBProtein kinase Bimatinib mesylateT315I mutationBcr-Ablcytotoxicitychronic myeloid leukemiaInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
BV02
Cat. No.:
HY-101985
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (399 KB) Français - FR (399 KB) Deutsch - DE (399 KB) Norwegian - NO (399 KB) Español - ES (399 KB) Swedish - SV (399 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.